| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/107327481402100305 |
| P698 | PubMed publication ID | 24955704 |
| P50 | author | Amit Mahipal | Q79225628 |
| P2093 | author name string | Aaron C Denson | |
| P2860 | cites work | Understanding the attitudes of the elderly towards enrolment into cancer clinical trials | Q25257182 |
| Prognostic indices for older adults: a systematic review | Q26865698 | ||
| Chemotherapy in elderly patients with gynecological cancer | Q33410185 | ||
| Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy | Q33601715 | ||
| The 2030 problem: caring for aging baby boomers | Q34623257 | ||
| Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience | Q34801461 | ||
| Projections of the cost of cancer care in the United States: 2010-2020. | Q35022830 | ||
| How does older age influence oncologists' cancer management? | Q35584140 | ||
| On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? | Q35611941 | ||
| Symptom management in the elderly cancer patient: fatigue, pain, and depression | Q35840887 | ||
| Never too old? Age should not be a barrier to enrollment in cancer clinical trials | Q36081341 | ||
| Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials | Q36110379 | ||
| A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). | Q36251468 | ||
| Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study | Q36760924 | ||
| Drivers and barriers to patient participation in RCTs | Q36775343 | ||
| Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score | Q39688507 | ||
| Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. | Q40410722 | ||
| Representation of older patients in cancer treatment trials | Q40704683 | ||
| Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment | Q40719431 | ||
| Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center | Q43455943 | ||
| Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign | Q43575954 | ||
| Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study | Q44058228 | ||
| Inclusion of frail elderly patients in clinical trials: solutions to the problems | Q45072379 | ||
| Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. | Q46848752 | ||
| Participation of patients 65 years of age or older in cancer clinical trials | Q48006693 | ||
| Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study | Q50117137 | ||
| Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials | Q50120629 | ||
| Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. | Q53064501 | ||
| Barriers to clinical trial participation by older women with breast cancer. | Q53860521 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 209-214 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Cancer Control | Q15724614 |
| P1476 | title | Participation of the elderly population in clinical trials: barriers and solutions | |
| P478 | volume | 21 |
| Q41704728 | Access to clinical trials among oncology patients: results of a cross sectional survey |
| Q90678141 | Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients |
| Q31163049 | Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group |
| Q47686048 | Barriers to Cancer Clinical Trial Participation Among Saudi Nationals: A Cross-Sectional Study. |
| Q39424807 | Cancer Research in the Arab World: A review of publications from seven countries between 2000-2013. |
| Q47945603 | Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). |
| Q49353073 | Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments |
| Q35896484 | Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden |
| Q36456924 | Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. |
| Q58750440 | Data Integration Innovations to Enhance Analytic Utility of Clinical Trial Content to Inform Health Disparities Research |
| Q35917852 | Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database |
| Q92762404 | Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies |
| Q89520863 | Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe? |
| Q53755910 | Exploring Willingness of Elder Chinese in Houston to Participate in Clinical Research. |
| Q93200655 | First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting |
| Q93160703 | Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70 |
| Q26781445 | Management of borderline resectable pancreatic cancer |
| Q55489780 | Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. |
| Q93101356 | Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape |
| Q36169867 | Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience |
| Q99711903 | Phase 1 Clinical Trials in the Elderly: Enrollment Challenges |
| Q36266597 | Reasons why patients fail screening in Indian breast cancer trials |
| Q55712411 | Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey☆. |
| Q39079683 | Responses to immune checkpoint inhibitors in nonagenarians |
| Q36512953 | Results of a Community Randomized Study of a Faith-Based Education Program to Improve Clinical Trial Participation among African Americans |
| Q38723729 | Same day admission for elective cardiac surgery: how to improve outcome with satisfaction and decrease expenses |
| Q36078698 | Special population considerations and regulatory affairs for clinical research |
| Q30399086 | Systematic errors in clinical studies : A comprehensive survey |
| Q33865329 | The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies |
| Q57169462 | Willingness to Participate in Vaccine-Related Clinical Trials among Older Adults |
| Q89916742 | [Systematic errors in clinical studies : A comprehensive survey] |
Search more.